Concord Biotech Limited
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.
What Concord files
- Investor Meet42
- Others42
- Important20
- Board Meeting13
- PPTs7
- Updates4
Concord Biotech Limited officials will attend a Group Meeting at an Investor Conference organized by Phillip Capital PCG in Ahmedabad on August 26, 2026, from 01:00 PM to 03:00 PM (IST). Discussions will be based solely on publicly available information.
Concord Biotech reported strong Q1 FY27 revenues of ₹257 Cr, up 26% YoY, with API segment growing 42% and exports surging 46%. Gross margins improved to 78.9%, and EBITDA reached ₹82 Cr (32% margin, up 190 bps YoY). Management is confident in sustaining momentum, targeting ₹3,000 Cr revenue in 5-6...
Concord Biotech successfully conducted an Earnings Call to discuss its unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026. An audio recording of the call is now available on the company's website.
Concord Biotech reported strong Q1FY27 financial results: Revenue jumped 26% to Rs 257.5 Cr, EBITDA grew 34% to Rs 82.4 Cr, and PAT increased 31% to Rs 57.7 Cr. Exports surged 46% YoY, driving broad-based growth across products and geographies. The company secured USFDA approvals for Mycophenolate Mofetil and Tofacitinib...
Concord Biotech Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on July 31, 2026. Further, the company has informed the Exchange regarding voting results.